<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The objective was to evaluate the protective effect of <z:chebi fb="1" ids="4775">ellagic acid</z:chebi> against experimentally induced <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo>, <z:mpath ids='MPATH_159'>hypertrophy</z:mpath> and its association with altered <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism during <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> in rats </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Rats were treated with <z:chebi fb="1" ids="4775">ellagic acid</z:chebi> (7.5 and 15 mg/kg) orally for a period of 10 days </plain></SENT>
<SENT sid="2" pm="."><plain>After 10 days of pretreatment, <z:chebi fb="0" ids="6046">isoproterenol</z:chebi> (100 mg/kg) was injected subcutaneously at an interval of 24 h for 2 days to induce <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>On the 12th day, the cardiac rhythm was observed </plain></SENT>
<SENT sid="4" pm="."><plain>The rats were sacrificed and the heart was isolated from each rat </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0001714'>Ventricular hypertrophy</z:hpo> and myocardial necrotic scores were analysed in the myocardium </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="23" ids="18059">Lipid</z:chebi> peroxidation products in the plasma were analysed </plain></SENT>
<SENT sid="7" pm="."><plain>Changes in the <z:chebi fb="23" ids="18059">lipid</z:chebi> profile were measured using the plasma and heart tissue homogenates of <z:mpath ids='MPATH_458'>normal</z:mpath> and experimental rats </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: <z:chebi fb="0" ids="6046">Isoproterenol</z:chebi>-induced rats showed <z:hpo ids='HP_0011675'>arrhythmias</z:hpo>, <z:mpath ids='MPATH_159'>hypertrophy</z:mpath> and increased levels of <z:chebi fb="2" ids="7044">myoglobin</z:chebi>, <z:chebi fb="2" ids="16919">creatine</z:chebi> kinase-MB, <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation products compared to the <z:mpath ids='MPATH_458'>normal</z:mpath> control rats </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0001714'>Ventricular hypertrophy</z:hpo> and increased myocardial necrotic scores were observed in <z:chebi fb="0" ids="6046">isoproterenol</z:chebi>-induced rats </plain></SENT>
<SENT sid="10" pm="."><plain>Oral pretreatment with <z:chebi fb="1" ids="4775">ellagic acid</z:chebi> restored pathological <z:hpo ids='HP_0011675'>arrhythmias</z:hpo>, <z:hpo ids='HP_0001714'>ventricular hypertrophy</z:hpo>, <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation, altered <z:chebi fb="23" ids="18059">lipid</z:chebi> profile and <z:hpo ids='HP_0001700'>myocardial necrosis</z:hpo> in the <z:chebi fb="0" ids="6046">isoproterenol</z:chebi>-induced myocardial infarcted rats </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Oral pretreatment with <z:chebi fb="1" ids="4775">ellagic acid</z:chebi> was safe and effective in cardio protection against ISO-induced <z:hpo ids='HP_0011675'>arrhythmias</z:hpo>, <z:mpath ids='MPATH_159'>hypertrophy</z:mpath> and <z:hpo ids='HP_0001700'>myocardial necrosis</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>Anti <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation property and anti hyperlipidaemic activity through 3-hydroxy-3 methyl <z:chebi fb="0" ids="15524">glutaryl CoA</z:chebi> reductase inhibition by <z:chebi fb="1" ids="4775">ellagic acid</z:chebi> may be the reasons for the beneficial action of <z:chebi fb="1" ids="4775">ellagic acid</z:chebi> against experimentally induced <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> </plain></SENT>
</text></document>